Stokes William A, Binder David C, Jones Bernard L, Oweida Ayman J, Liu Arthur K, Rusthoven Chad G, Karam Sana D
Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA.
J Neuroimmunol. 2017 Dec 15;313:118-122. doi: 10.1016/j.jneuroim.2017.10.006. Epub 2017 Oct 13.
Patients with melanoma brain metastases (MBM) have been excluded from trials evaluating immunotherapy in melanoma. As such, immunotherapy's role in MBM is poorly understood, particularly in combination with radiotherapy.
The National Cancer Database was queried for patients with MBM receiving brain radiotherapy. They were classified according to immunotherapy receipt. Multivariate Cox regression was performed to identify factors associated with survival.
Among 1287 patients, 185 received immunotherapy. Factors associated with improved survival included younger age, academic facility, lower extracranial disease burden, stereotactic radiotherapy, chemotherapy, and immunotherapy.
Adding immunotherapy to radiotherapy for MBM is associated with improved survival.
黑色素瘤脑转移（MBM）患者被排除在评估黑色素瘤免疫疗法的试验之外。因此，免疫疗法在MBM中的作用了解甚少，尤其是与放疗联合使用时。
在国家癌症数据库中查询接受脑部放疗的MBM患者。根据是否接受免疫疗法对他们进行分类。进行多变量Cox回归以确定与生存相关的因素。
在1287例患者中，185例接受了免疫疗法。与生存改善相关的因素包括年龄较小、学术机构、颅外疾病负担较低、立体定向放疗、化疗和免疫疗法。
在MBM放疗中添加免疫疗法与生存改善相关。
